



Published in final edited form as:

Cancer Treat Res Commun. 2026 ; 47: 101240. doi:10.1016/j.ctarc.2026.101240.

Corrigendum to “KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status” [Cancer Treatment and Research Communications 47 (2026) 101227]

Ziheng Xu^a, Jacqueline V. Aredo^b, Chloe C. Su^c, Nathaniel J. Myall^b, Mohana Roy^b, Kavitha J. Ramchandran^b, Heather A. Wakelee^b, Joel W. Neal^{b,*}

^aDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA

^bDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

^cQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA

The authors would like to include the following disclosure of potential conflicts of interest. The authors would like to apologise for any inconvenience caused.

Jacqueline Aredo:

Advisory/consulting role: AstraZeneca, Johnson & Johnson, Bristol Myers Squibb

Honorarium: Binaytara Foundation, Kaplan, IDEOlogy Health

Chloe Su:

Advisory/consulting role: Revamp Medical

Employment, travel: Revolution medicines

Equity and stocks: 10x Genomics, Teladoc Health, Moderna, Revolution medicines

Nathaniel Myall:

Advisory/consulting role: Nuvalent Inc.

Funding grants: Genentech, BlossomHill Therapeutics

Heather Wakelee:

Advisory/consulting role: IoBiotech, BeOne, GSK, Regeneron

Equity or stocks (stock option only) and advisory/consulting role: OncoC4

This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).

*Corresponding author. jwneal@stanford.edu (J.W. Neal).

Funding grants: Henlius, Xcovery, Glead

Funding grants and advisory/consulting role: AstraZeneca, Gen entech/Roche, Merck, Pfizer (SeaGen)